Naltrexone extended release plus bupropion extended release for treatment of obesity

JAMA - Journal of the American Medical Association

Volumn 313, Issue 12, 2014, Pages 1213-1214

  Yanovski, Susan Z ^a   Yanovski, Jack A ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; AMFEBUTAMONE PLUS NALTREXONE; LIRAGLUTIDE; LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; PROOPIOMELANOCORTIN; TETRAHYDROLIPSTATIN; AMFEBUTAMONE; ANTIOBESITY AGENT; BUPROPION HYDROCHLORIDE, NALTREXONE HYDROCHORIDE DRUG COMBINATION; DRUG COMBINATION; NALTREXONE;

BODY MASS; CARDIOVASCULAR DISEASE; COMORBIDITY; CONSTIPATION; DIARRHEA; DIET THERAPY; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXERCISE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HORMONE RELEASE; HUMAN; HYPERTENSION; INSOMNIA; LIFESTYLE MODIFICATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME; UNITED STATES; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; DRUG COMBINATION;

ANTI-OBESITY AGENTS; BUPROPION; DRUG COMBINATIONS; HUMANS; NALTREXONE; OBESITY; WEIGHT LOSS;

EID: 84925431365     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.1617     Document Type: Short Survey

References (10)

1. Contrave (naltrexone HCl and bupropion HCl) Extended-Release Tablets [package insert revised 9/2014]. La Jolla, CA: Orexigen Therapeutics; 2014.
2. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74-86.
3. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-546.
4. Greenway FL, Fujioka K, Plodkowski RA, et al COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I). Lancet. 2010;376(9741):595-605.
5. Apovian CM, Aronne L, Rubino D, et al COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935-943.
6. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110-120.
7. Hollander P, Gupta AK, Plodkowski R, et al COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022-4029.
8. FDA Briefing Document. Orexigen Therapeutics Inc, data on file. New Drug Application 200063: Contrave (Naltrexone 4mg, 8mg/Bupropion HCL 90mg extended release tablet). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm235671.pdf. Accessed February 12, 2015.
9. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. J Am Coll Cardiol. 2014;63(25 pt B):2985-3023.
10. Orexigen announces successful interim analysis of Contrave Light study. http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1879629. 2013. Accessed December 13, 2014.